Invivyd Inc.
$ 0.77
-5.23%
12 Jun - close price
- Market Cap 239,369,000 USD
- Current Price $ 0.77
- High / Low $ 0.88 / 0.73
- Stock P/E N/A
- Book Value 0.72
- EPS -0.29
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.30 %
- ROE -0.60 %
- 52 Week High 3.07
- 52 Week Low 0.48
About
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases in the United States. The company is headquartered in Waltham, Massachusetts.
Analyst Target Price
$10.00
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-14 | 2026-03-05 | 2025-11-06 | 2025-08-14 | 2025-05-15 | 2025-03-20 | 2024-11-14 | 2024-08-14 | 2024-05-09 | 2024-03-28 | 2023-11-09 | 2023-08-10 |
| Reported EPS | -0.13 | -0.0393 | -0.06 | -0.12 | -0.14 | -0.15 | -0.51 | -0.4 | -0.38 | -0.67 | -0.36 | -0.46 |
| Estimated EPS | -0.0556 | -0.0864 | -0.07 | -0.02 | -0.01 | -0.1 | -0.35 | -0.37 | -0.47 | -0.42 | -0.5 | -0.34 |
| Surprise | -0.0744 | 0.0471 | 0.01 | -0.1 | -0.13 | -0.05 | -0.16 | -0.03 | 0.09 | -0.25 | 0.14 | -0.12 |
| Surprise Percentage | -133.8129% | 54.5139% | 14.2857% | -500% | -1300% | -50% | -45.7143% | -8.1081% | 19.1489% | -59.5238% | 28% | -35.2941% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: IVVD
2026-06-12 03:39:25
Invivyd Inc (NASDAQ: IVVD) has completed enrollment for its DECLARATION Phase 3 clinical trial of the Covid-19 drug candidate VYD2311, with topline data expected in Q3 2026. Analysts predict over 750% upside potential for the stock, which has already gained 30% in the past year, making it a focus for investors interested in biopharmaceutical developments. The company's antibody technology platform, which uses the same backbone as the FDA-authorized pemivibart, aims to develop therapies for serious viral infectious diseases.
2026-06-10 21:11:00
This article highlights Invivyd Inc (NASDAQ: IVVD) as one of billionaire Lee Ainslie's top stock picks with significant upside potential. The company's stock has seen a 30% gain over the past year, with analysts projecting over 750% growth in the next 12 months. The optimism stems from the completion of enrollment in its Phase 3 clinical trial for its Covid-19 drug candidate, VYD2311, with topline data expected in Q3 2026.
2026-06-10 08:40:28
This article provides a detailed financial breakdown for Invivyd Inc (IVVD) and Vericel Corp (VCEL). It presents key financial metrics such as market capitalization, P/E ratios, sales, EPS, insider ownership, and institutional ownership for both biotechnology companies. The data includes performance over various periods, profitability ratios, and balance sheet figures to offer a comprehensive financial overview.
2026-06-09 11:39:05
Invivyd, Inc. has begun dosing participants in its LIBERTY Phase 3 clinical trial, which aims to evaluate the safety and tolerability of its VYD2311 vaccine-alternative monoclonal antibody (mAb) compared to an mRNA COVID-19 vaccine, and to assess co-administration. This trial is part of Invivyd's broader REVOLUTION clinical program, with topline data from LIBERTY expected in Q3 2026, alongside data from the DECLARATION trial. The company believes VYD2311 could offer a more tolerable COVID-19 prevention option than traditional vaccines.
2026-06-09 11:39:05
Invivyd (NASDAQ: IVVD) has begun dosing participants in its Phase 3 LIBERTY clinical trial to evaluate the safety, tolerability, and immunology of its investigational monoclonal antibody candidate, VYD2311, alone and co-administered with an mRNA COVID-19 vaccine. The study aims to enroll approximately 210 healthy adults across three cohorts and is part of Invivyd's broader REVOLUTION clinical development program. Topline data from the LIBERTY trial is targeted for Q3 2026, coinciding with the DECLARATION trial data release, to support future regulatory filings.
2026-06-09 10:39:05
Invivyd (IVVD) has commenced its Phase 3 LIBERTY clinical trial, dosing the first participants to evaluate the safety and tolerability of its VYD2311 antibody against mRNA COVID vaccines, and also the co-administration of both. This trial, involving approximately 210 healthy adults, aims to provide an alternative COVID-19 prevention option that may have a more favorable tolerability profile compared to traditional vaccines. Topline data from the LIBERTY trial is anticipated in Q3 2026 and will support future regulatory filings for VYD2311.
